The molecular structure of BEI-258 has not been made public. According to their website, Beiwei is focused on the development of mTORC-1 Inhibitors. mTORC1 inhibitors specifically target and inhibit the mTORC1 complex as opposed to inhibition of both MTORC-1 and MTORC-2. Rapamycin was the first known MTORC inhibitor, by binding to FKBP12 and then interacting with mTORC1, leading to its inhibition. These inhibitors primarily affect protein synthesis, autophagy, and lipid metabolism and have been shown to extend life in animal studies. mTORC Inhibitors inhibit the mTOR kinase activity directly, affecting both complexes’ functions. Examples of such inhibitors include small molecules like Torin1 and AZD8055. By inhibiting both complexes, mTORC inhibitors can potentially offer broader therapeutic effects, but they also come with a higher risk of side effects due to the inhibition of multiple pathways. Sundeep Dugar, the CSO of Beiwe has published two papers on mTORC inhibitors including SPR519 as a Potent, Selective and Orally Bioavailable Inhibitor of PI3Kalpha for the treatment of solid tumors. and SPR965 is a potent inhibitor of PI3K alpha and mTOR. SPR965 is also a highly selective inhibitor of PI3 and mTOR C1/C2 kinases when evaluated in a screen against 456 kinases.